Atjaunināt sīkdatņu piekrišanu

Microbial Crosstalk with Immune System: New Insights in Therapeutics [Mīkstie vāki]

Edited by (Assistant Professor, Department of Biotechnology, Delhi Technological University, Govt. of Delhi, NCT, Shahbad, India)
  • Formāts: Paperback / softback, 272 pages, height x width: 235x191 mm, weight: 570 g
  • Sērija : Developments in Immunology
  • Izdošanas datums: 29-Jul-2022
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0323961282
  • ISBN-13: 9780323961288
Citas grāmatas par šo tēmu:
  • Mīkstie vāki
  • Cena: 178,26 €
  • Grāmatu piegādes laiks ir 3-4 nedēļas, ja grāmata ir uz vietas izdevniecības noliktavā. Ja izdevējam nepieciešams publicēt jaunu tirāžu, grāmatas piegāde var aizkavēties.
  • Daudzums:
  • Ielikt grozā
  • Piegādes laiks - 4-6 nedēļas
  • Pievienot vēlmju sarakstam
Microbial Crosstalk with Immune System: New Insights in TherapeuticsPalielināt
  • Formāts: Paperback / softback, 272 pages, height x width: 235x191 mm, weight: 570 g
  • Sērija : Developments in Immunology
  • Izdošanas datums: 29-Jul-2022
  • Izdevniecība: Academic Press Inc
  • ISBN-10: 0323961282
  • ISBN-13: 9780323961288
Citas grāmatas par šo tēmu:
Permanent link: https://www.kriso.lv/db/9780323961288.html
Keywords:

Our body is not sterile and harbors enumerable microflora that are now being understood to play a complex role in immune regulation and shaping of the immune system in a continuous and dynamic way. In 8 chapters, Microbial Crosstalk with Immune System: New Insights in Therapeutics provides an overall introduction with special focus on how the immune system which is specifically geared to get rid of non-self-antigens, allows numerous microbes to colonize the human body. In the presence of microbes there are several observations that suggest that there are multiple roles that are played by these microbes in tumor progression and shaping of our immune system which is explained at length in subsequent chapters.

Microbial Crosstalk with Immune System: New Insights in Therapeutics discusses the emerging mechanisms of immune-therapeutics as well as its limitations while emphasizing the potential role of microbes in shaping immune-therapeutic and evolving novel strategies to deal with any limitations.

  • Focuses on the modulation of immune system by the microbiome, thus affecting cancer prognosis
  • Discusses various current research strategies in the field that are still in experimental stages. enabling readers to gain a perspective on the ongoing research in the field
  • Gives insight into the emerging mechanisms of immune-therapeutics and its limitations
  • Emphasizes the potential role of microbes in shaping immune-therapeutics
List of contributors
xi
Chapter 1 Introduction
1(20)
Asmita Das
Saksham Garg
1.1 Host immune response against infections
1(2)
1.2 Increased tolerization in gut
3(2)
1.3 Dynamics of gut microbiota and its dependency on external factors
5(3)
1.3.1 Dynamic nature across various stages of life
5(2)
1.3.2 Other factors affecting gut microbiota
7(1)
1.4 Cancer and its hallmarks
8(4)
1.4.1 Self-sufficiency in signaling growth factors
8(1)
1.4.2 Insensitivity to antigrowth signals
9(1)
1.4.3 Evading apoptosis
9(1)
1.4.4 Limitless replicative potential
10(1)
1.4.5 Sustained angiogenesis
10(1)
1.4.6 Tissue invasion and metastasis
11(1)
1.4.7 Emerging hallmark: reprogramming cell energetics
11(1)
1.4.8 Emerging hallmark: immune evasion
11(1)
1.5 Involvement of immune system in cancer
12(1)
1.6 Microbiota and cancer
13(8)
References
14(7)
Chapter 2 Significance of the normal microflora of the body
21(18)
Varsha Gupta
Baishnab Charan Tripathy
Neelima Gupta
Jaya Prakash
2.1 Introduction
21(2)
2.2 Normal microflora
23(3)
2.3 Human microbiome
26(9)
2.3.1 Microbiota of the gut
26(3)
2.3.2 Microbiota in other parts of the human body
29(2)
2.3.3 Functions of microbiota
31(4)
2.4 Conclusion
35(4)
References
35(4)
Chapter 3 Immunological paradox for maintaining normal flora: it is all by design, not by chance
39(36)
Deeksha Mehtani
Niti Puri
3.1 Microflora in the development of immune system
39(3)
3.1.1 Effect of mode of birth on microbial colonization and immune system development
39(1)
3.1.2 Understanding from germ-free animal experiments
40(2)
3.2 Immune system tolerance of microflora
42(8)
3.2.1 Compartmentalization of microflora
42(1)
3.2.2 Microflora and the innate immune system
43(7)
3.3 Protective role of short-chain fatty acids in inflammation and cancer prevalence
50(1)
3.4 Microflora and adaptive immune system
51(3)
3.4.1 Interplay between humoral immunity and microflora
52(1)
3.4.2 Interplay between T cell-mediated immunity and microflora
53(1)
3.5 Environmental factors altering microflora and influencing immune system
54(2)
3.5.1 Impact of antibiotics usage on microflora and host immunity
54(1)
3.5.2 Effects of prebiotics in the host's diet on microflora
55(1)
3.5.3 Effects of type of diet on microflora
56(1)
3.6 Microflora dysbiosis in disease and impact on immune system
56(3)
3.6.1 Microflora and inflammatory bowel diseases
57(1)
3.6.2 Microflora and neurodegenerative diseases
58(1)
3.6.3 Microflora and allergic diseases
59(1)
3.7 Conclusion
59(16)
Acknowledgments
61(1)
References
61(14)
Chapter 4 Cancer prognosis and immune system
75(70)
Shayon Mahalanobis
Apoorva
Nikita Sharma
Ritika Luthra
Tarunya Menon
Asmita Das
4.1 Introduction
75(1)
4.2 Defining pathology
76(1)
4.3 Molecular pathology
77(1)
4.4 Need for molecular diagnosis
78(1)
4.5 Techniques involved in molecular diagnosis
78(1)
4.5.1 Microarray
78(1)
4.5.2 Immunohistochemistry
79(1)
4.5.3 Polymerase chain reaction
79(1)
4.5.4 Liquid biopsy
79(1)
4.6 Pathological and molecular aspects of different cancers
79(12)
4.6.1 Colorectal cancer
79(4)
4.6.2 Breast
83(1)
4.6.3 Ovarian
84(2)
4.6.4 Lung
86(1)
4.6.5 Thyroid
87(1)
4.6.6 Liver
88(2)
4.6.7 Prostate
90(1)
4.7 Artificial intelligence in studying cancer pathology
91(2)
4.8 Immune system: innate and adaptive immunity
93(18)
4.8.1 Role of immune system in cancer progression
93(2)
4.8.2 Inflammation and tumorigenesis
95(3)
4.8.3 Changes in tumor microenvironment with cancer progression
98(10)
4.8.4 Cross talk between cancer heterogeneity and immune system
108(3)
4.9 Conclusion
111(34)
References
112(33)
Chapter 5 Human microbiota: role in cancer progression and therapy
145(32)
Anam Rais
Preeti Chand
Megha Malik
Tulika Prasad
5.1 Introduction
145(1)
5.2 Relationship between human microbiota and cancer
146(2)
5.3 Conventional therapies used for treatment of cancer
148(3)
5.4 Role of microbiota in cancer progression
151(5)
5.4.1 Microbial-associated molecular patterns
151(2)
5.4.2 Secondary toxic metabolites
153(1)
5.4.3 Poly amines
153(1)
5.4.4 Microbial virulence factors
154(1)
5.4.5 Fermentation products and catabolites
154(1)
5.4.6 Pathogenic bacteria cytokine
155(1)
5.5 Role of microbiota in cancer regression and therapy
156(5)
5.5.1 Metabolites
157(1)
5.5.2 Prebiotics/probiotics
158(1)
5.5.3 Targeting pathogenic microbial pathways
159(1)
5.5.4 Antibiotics
160(1)
5.5.5 Fecal microbiota transplantation/bacteriotherapy
160(1)
5.6 Challenges, gaps, and future perspectives
161(3)
5.7 Conclusion
164(13)
Acknowledgments
164(1)
References
164(13)
Chapter 6 Microflora impacts immune system and its antitumor function
177(30)
Priyanka Rawat
Muskaan Dhingra
Kashish Kosta
Asmita Das
6.1 Introduction
177(1)
6.2 Cancer immunotherapy
177(6)
6.2.1 Cancer-immunity cycle
178(1)
6.2.2 Classification of cancer immunotherapy
179(3)
6.2.3 MAGE (Melonoma Antigen)
182(1)
6.2.4 CCL21 (Chemokine (C-C motif) ligand 21)
182(1)
6.2.5 SLC39A1 (Solute Carrier Family 39 Member 1)
183(1)
6.3 Diverse microflora in humans
183(6)
6.3.1 Composition
183(1)
6.3.2 Functions
184(1)
6.3.3 Metabolites and their impact
184(1)
6.3.4 Mechanism of interaction of gut microbiota with host
185(1)
6.3.5 Microbes for immunotherapy
186(1)
6.3.6 Probiotics and immune system
187(1)
6.3.7 Effect of antibiotics on microbiota and immune system
188(1)
6.4 Microbiota, disease development, and effect on immune system
189(1)
6.4.1 Obesity
189(1)
6.4.2 Colon cancer
190(1)
6.4.3 Inflammatory bowel disease (IBD)
190(1)
6.5 Microbes and autoimmune diseases
190(4)
6.5.1 Type 1 diabetes
190(1)
6.5.2 Multiple sclerosis
191(1)
6.5.3 Rheumatoid arthritis
192(1)
6.5.4 Systemic lupus erythematosus
192(1)
6.5.5 Use of probiotics in autoimmune disorders
193(1)
6.6 Evidence for the antitumor function of microflora
194(5)
6.7 Conclusion
199(8)
References
199(8)
Chapter 7 Cancer therapeutics and gut microflora
207(26)
Shruti Ahlawat
Asha
Krishna Kant Sharma
7.1 Cancer: biology and treatment
207(1)
7.2 Gut microbiota: an organ in itself!
208(2)
7.3 Gut microbiota, immune system, and cancer development
210(1)
7.4 Role of gut microbiota in cancer therapy
211(14)
7.4.1 Metabolic and immune checkpoints in tumor microenvironment
211(1)
7.4.2 Gut microbiota in chemotherapy
212(6)
7.4.3 Gut microbiota in immunotherapy
218(4)
7.4.4 Gut microbiota in radiotherapy
222(3)
7.5 Conclusion
225(8)
Conflict of interest
225(1)
Author contributions
225(1)
Funding
226(1)
References
226(7)
Chapter 8 Missing rungs in cancer therapeutics and strategies to climb them
233(18)
Rinu Sharma
Aprajita
8.1 Surgery--radiation-chemo-therapy
233(6)
8.1.1 Delayed diagnosis
233(1)
8.1.2 Improvising diagnosis
233(3)
8.1.3 Side effects
236(1)
8.1.4 Radioresistance
237(1)
8.1.5 Chemoresistance
238(1)
8.2 Genomically targeted therapy
239(1)
8.2.1 Side effects
240(1)
8.2.2 Comprehensive genomic profding
240(1)
8.3 Cancer immunotherapy
240(1)
8.4 Upcoming therapies
241(2)
8.4.1 Extrachromosomal DNA-targeted therapy
241(1)
8.4.2 Metabolic therapy
242(1)
8.5 Advancements in therapeutic procedure
243(3)
8.5.1 Thermal ablation
243(1)
8.5.2 Magnetic hyperthermia
244(1)
8.5.3 Liquid biopsy
244(1)
8.5.4 Circulating tumor cells
245(1)
8.5.5 Cell-free DNA
245(1)
8.6 Microbes in cancer therapeutics
246(1)
8.7 Biobanking of cancer samples
246(1)
8.8 Centralized data curation
246(2)
8.9 Affordability of cancer treatment
248(3)
8.9.1 Managing affordable cancer care
248(1)
8.9.2 Reducing procedures with little or no value
249(1)
8.9.3 Coordinated and efficient care
250(1)
8.9.4 Improving functionality of electronic medical records
250(1)
8.9.5 Prioritizing cancer prevention
250(1)
References 251(2)
Index 253
Dr. Asmita Das completed her PhD from School of Life Sciences, Jawaharlal Nehru University and thereafter joined National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA for a postdoctoral position for about 5 years.

She has since been employed in Delhi Technological University since 2010 as Assistant Professor. Her research interests include Immunotherapeutics and Immunoinformatics. She is also involved in various interdisciplinary research. She has published several high impact peer reviewed papers including Immunity (IF: 21), Autophagy (IF: 11), Journal of Immunology (IF: 5.6) (top 10% articles in the journal in 2010) and many others. She serves on the editorial board of several peer reviewed journals. She has been actively involved in Industry- Academia partnership, including research guidance of industry personnel. She has served in several selection boards, external examiners and invited speakers in several institutes of repute.